Colinz Labs

Which are the latest news on Colinz Labs?

Should I buy, sell or hold Colinz Laboratories Ltd?

Why is Colinz Laboratories Ltd falling/rising?

As of 20-Jun, Colinz Laboratories Ltd's stock price is rising to 62.18, reflecting a 5.0% increase and strong performance over various periods, notably a 40.71% rise in the past month. Despite a significant drop in investor participation, the stock maintains sufficient liquidity and continues to outperform benchmarks.

As of 20-Jun, Colinz Laboratories Ltd's stock price is rising, currently at 62.18, reflecting a change of 2.96 (5.0%) upwards. The stock has shown strong performance over various periods, with a notable increase of 40.71% over the past month, significantly outperforming the Sensex, which only rose by 2.13% in the same timeframe. Additionally, the stock has gained 13.72% over the past week, again surpassing the Sensex's 1.69% increase.<BR><BR>Today's trading activity indicates a positive trend, as the stock opened with a gain of 5% and has maintained this price throughout the day. It has also outperformed its sector by 4.28%. The stock has been on a consecutive gain streak for the last two days, accumulating a total return of 6.75% during this period. Furthermore, Colinz Laboratories Ltd is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which suggests a strong upward momentum.<BR><BR>However, it is important to note that there has been a significant drop in investor participation, with delivery volume on 17 June falling by 99.86% compared to the 5-day average. Despite this decline in participation, the stock's liquidity remains sufficient for trading. Overall, the combination of strong recent performance, positive daily trading activity, and favorable comparisons to benchmarks contributes to the rising stock price of Colinz Laboratories Ltd.

How big is Colinz Labs?

As of 10th June, Colinz Laboratories Ltd has a market capitalization of 15.00 Cr, with recent net sales of 6.14 Cr and a net profit of 0.51 Cr. Shareholder's funds are 9.47 Cr, and total assets amount to 11.82 Cr.

As of 10th June, Colinz Laboratories Ltd has a market capitalization of 15.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Colinz Laboratories Ltd reported Net Sales of 6.14 Cr and a Net Profit of 0.51 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 9.47 Cr and Total Assets of 11.82 Cr.

Who are in the management team of Colinz Labs?

The management team of Colinz Labs consists of L S Mani (Director & Company Secretary), N K Menon (Whole-time Director), Vasant K Bhat (Independent Director), and A Krishna Kumar (Independent Director).

The management team of Colinz Labs includes the following individuals:<BR><BR>1. L S Mani - Director & Company Secretary<BR>2. N K Menon - Whole-time Director<BR>3. Vasant K Bhat - Independent Director<BR>4. A Krishna Kumar - Independent Director<BR><BR>If you need more details about their roles or the company, feel free to ask!

Who are the peers of the Colinz Labs?

Colinz Labs' peers include Parmax Pharma, Desh Rakshak, Dipna Pharmachem, and others, with varying management and growth risks. Parmax Pharma leads in 1-year returns at 48.68%, while Colinz Labs has a return of -7.60%.

Peers: The peers of Colinz Labs are Parmax Pharma, Desh Rakshak, Dipna Pharmachem, Starsource Multi, Zenith Health, Ortin Global, Beryl Drugs, Unjha Formul., and Saroja Pharma In.<BR><BR>Quality Snapshot: Below Average management risk is observed at Parmax Pharma, Desh Rakshak, Dipna Pharmachem, Zenith Health, Ortin Global, Beryl Drugs, and the rest. Average management risk is found at Unjha Formul. and Saroja Pharma In. Excellent growth is noted at Dipna Pharmachem, while Below Average growth is seen at Parmax Pharma, Desh Rakshak, Zenith Health, Ortin Global, Beryl Drugs, and the rest. Average growth is present at Unjha Formul. and Saroja Pharma In. Good capital structure is noted at Zenith Health, Colinz Labs, and Unjha Formul., while Below Average capital structure is found at Parmax Pharma, Desh Rakshak, Dipna Pharmachem, Ortin Global, Beryl Drugs, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Parmax Pharma at 48.68%, while the peer with the lowest is Dipna Pharmachem at -66.76%. Colinz Labs has a 1-year return of -7.60%, which is better than Dipna Pharmachem but worse than Parmax Pharma. Additionally, the six-month returns are negative for Dipna Pharmachem, Zenith Health, and Saroja Pharma In.

What does Colinz Labs do?

Colinz Laboratories Ltd is a pharmaceutical and biotechnology company that manufactures various pharmaceutical formulations. As of March 2026, it reported net sales of 2 Cr and a market cap of INR 15 Cr.

Overview:<BR>Colinz Laboratories Ltd is a pharmaceutical and biotechnology company that manufactures a wide variety of pharmaceutical formulations.<BR><BR>History:<BR>Colinz Laboratories Ltd was incorporated as a Private Limited Company in 1986 and converted into a Public Limited Company in 1995, the same year it commenced manufacturing and marketing activities. The latest quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 2 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 15 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 28.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.68 <BR>Return on Equity: 5.16% <BR>Price to Book: 1.50 <BR><BR>Contact Details:<BR>Address: A-101 Pratik Industrial Estate, Mulund Goregaon Link Road Mumbai Maharashtra : 400078 <BR>Tel: 91-022-25668002/8003 <BR>Email: colinzlabs@yahoo.com <BR>Website: http://www.cindoc-cll.in

Are Colinz Laboratories Ltd latest results good or bad?

Colinz Laboratories Ltd's latest quarterly results show significant improvement with a 112.50% increase in net profit and a 22.38% rise in net sales. However, the annual performance is concerning due to a 14.30% decline in sales and a low return on equity of 4.96%, indicating potential long-term challenges.

Colinz Laboratories Ltd's latest results present a mixed picture. In Q4 FY25, the company reported a net profit of ₹0.17 crores, which is a significant increase of 112.50% compared to the previous quarter. Additionally, net sales rose to ₹1.75 crores, reflecting a 22.38% quarter-on-quarter growth and a 20.69% year-on-year increase. The profit after tax margin also improved to 9.71%, up from 5.59% in the previous quarter.<BR><BR>However, despite these positive quarterly results, the overall performance for FY25 shows a concerning trend. The company's annual sales declined by 14.30% compared to FY24, indicating a shrinking revenue base. Furthermore, the return on equity (ROE) remains low at 4.96%, suggesting inefficiencies in generating returns for shareholders.<BR><BR>The stock has been volatile, trading significantly below its 52-week high, and there is a lack of institutional interest, which raises questions about long-term sustainability. Overall, while the quarterly results show improvement, the broader context of declining annual sales and weak return metrics suggests that the company's situation is more complex and potentially troubling.

When is the next results date for Colinz Laboratories Ltd?

The next results date for Colinz Laboratories Ltd is April 29, 2026.

The next results date for Colinz Laboratories Ltd is scheduled for April 29, 2026.

Is Colinz Labs overvalued or undervalued?

As of November 3, 2025, Colinz Labs is overvalued with a PE ratio of 42.76 and a year-to-date decline of 35.64%, indicating a concerning long-term outlook despite a recent short-term gain.

As of 3 November 2025, Colinz Labs has moved from a fair to an expensive valuation grade. The company is currently overvalued, with a PE ratio of 42.76, an EV to EBIT of 15.61, and a ROE of 5.07%. In comparison to its peers, Sun Pharma has a PE of 35.62 and an EV to EBITDA of 24.18, while Cipla shows a more attractive PE of 22.44 and an EV to EBITDA of 5.66, highlighting Colinz Labs' relatively high valuation metrics.<BR><BR>Despite a recent uptick in stock price, with a 1-week return of 3.46% compared to a -0.94% return on the Sensex, the overall performance year-to-date shows a decline of 35.64% against a 7.47% increase in the Sensex. This suggests that while there may be short-term gains, the long-term outlook for Colinz Labs remains concerning given its current overvaluation in the context of its peers.

How has been the historical performance of Colinz Labs?

Colinz Labs has experienced a downward trend in net sales, reporting 6.53 Cr in March 2025, down from 7.03 Cr in March 2024. Despite a slight increase in profit after tax to 0.50 Cr, negative cash flow and declining revenues raise concerns about its financial stability.

Answer:<BR>The historical performance of Colinz Labs shows a fluctuating trend in net sales and profits over the years, with a slight decline in recent periods.<BR><BR>Breakdown:<BR>Colinz Labs reported net sales of 6.53 Cr in March 2025, down from 7.03 Cr in March 2024 and 7.15 Cr in March 2023, indicating a downward trend in revenue. The total operating income mirrored this decline, remaining at 6.53 Cr in March 2025. The company's total expenditure, excluding depreciation, decreased to 6.03 Cr in March 2025 from 6.49 Cr in March 2024. Operating profit (PBDIT) was 0.80 Cr in March 2025, slightly lower than 0.82 Cr in March 2024, while profit before tax was 0.62 Cr, down from 0.65 Cr the previous year. Profit after tax showed a modest increase to 0.50 Cr in March 2025 from 0.49 Cr in March 2024. The company's total assets rose to 11.82 Cr in March 2025 from 11.36 Cr in March 2024, and total liabilities also increased to 11.82 Cr from 11.36 Cr. Cash flow from operating activities turned negative at -1.00 Cr in March 2025, contrasting with a positive inflow of 1.00 Cr in March 2024. Overall, while Colinz Labs has shown some resilience in profit margins, the decline in sales and cash flow raises concerns about its financial stability.

Who are the top shareholders of the Colinz Labs?

The top shareholder of Colinz Labs is Mani L S, holding 34.45% of the shares, with no pledged promoter holdings. The highest public shareholder is Dipakbhai Haribhai Gaudani at 1.31%, while individual investors collectively own 31.04%.

The top shareholders of Colinz Labs include the promoters, with Mani L S holding the largest share at 34.45%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Dipakbhai Haribhai Gaudani, who holds 1.31%. Additionally, individual investors collectively hold 31.04% of the shares.

What is the technical trend for Colinz Labs?

As of 26 May 2025, Colinz Labs shows a bullish technical trend supported by positive daily and weekly indicators, although caution is advised due to mildly bearish signals from the monthly MACD and Dow Theory.

As of 26 May 2025, the technical trend for Colinz Labs has changed from mildly bullish to bullish. The weekly MACD is bullish, supporting the upward momentum, while the daily moving averages also indicate a bullish stance. The KST is bullish on both weekly and monthly time frames, reinforcing the positive outlook. However, the monthly MACD and Dow Theory show mildly bearish signals, suggesting some caution. Overall, the current technical stance is bullish with moderate strength, driven primarily by the bullish indicators on the daily and weekly charts.

Has Colinz Labs declared dividend?

No Dividend History Available